Abstract
Background: BAL0891 is a first-in-class dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). Both kinases collaborate in activating the spindle assembly checkpoint (SAC) to regulate chromosome alignment and segregation before the cell can exit mitosis. In vitro treatment of tumor cells with BAL0891 leads to rapid SAC disruption and accumulation of cells with aberrant chromosome numbers. The resultant genetic instability suggests a potential for combination effects with approved cytotoxic therapies, such as paclitaxel and carboplatin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
